Literature DB >> 971352

Effects of clofibrate treatment on plasma triglyceride concentration, plasma post-heparin clearing factor lipase (lipoprotein lipase) activity and serum clearing factor lipase activating ability in maturity-onset diabetes.

M P Rogers, D Barnett, D S Robinson.   

Abstract

The effects of clofibrate on plasma triglyceride concentration, plasma post-heparin clearing factor lipase activity and serum clearing factor lipase activating ability were studied in a group of maturity-onset diabetic patients. Significant falls in both triglyceride concentration and in activating ability occurred within 2 weeks of beginning clofibrate treatment and, when treatment was stopped after 4 weeks, these changes were reversed within a further 4 weeks. Plasma post-heparin clearing factor lipase activity, on the other hand, was significantly increased during clofibrate administration and fell again when the treatment was stopped. The possible interrelationships of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971352     DOI: 10.1016/0021-9150(76)90148-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

1.  Lipid and lipoprotein metabolism in familial combined hyperlipidaemia during treatment of sporadic phaeochromocytoma: a case study.

Authors:  P H Winocour; T Masud; F Clark; B G Cooper; M F Laker; K G Alberti
Journal:  Postgrad Med J       Date:  1992-05       Impact factor: 2.401

2.  Plasma lipoproteins and lipoprotein lipase in young diabetics with and without ketonuria.

Authors:  P Rubba; B Capaldo; A Falanga; S Caprio; A Rivellese; G Riccardi; M Mancini
Journal:  J Endocrinol Invest       Date:  1985-10       Impact factor: 4.256

3.  A case of association between type I hyperlipoproteinemia and systemic lupus erythematosus (SLE). Effects of steroid treatment.

Authors:  P Pauciullo; B De Simone; P Rubba; M Mancini
Journal:  J Endocrinol Invest       Date:  1986-12       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.